Metastatic kidney cancer patients who took a proprietary live bacterial supplement showed signs that it could improve their outcomes in a Phase I trial of cabozantinib and nivolumab, according to researchers.
In a social media landscape shaped by hashtags, algorithms, and viral posts, nurse leaders must decide: Will they let the narrative spiral, or can they adapt and join the conversation?
...
